A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

This postmarketing study is a randomized, double-blind, placebo-controlled study to evaluate
safety (with particular focus on renal and cardiovascular events) and efficacy of lesinurad
200 mg QD in combination with an XOI for up to 24 months compared with XOI monotherapy, in
participants with gout and moderate renal impairment who have not reached target sUA levels
(<6.0 mg/dL) on an XOI alone.

Inclusion Criteria:

1. Subject is able to understand the study procedures, the risks involved, and willing to
provide written informed consent before the first study related activity.

2. Subject is willing to adhere to the protocol schedule.

3. Subject is ≥18 years and ≤85 years of age.

4. Subject has a diagnosis of gout.

5. Subject has moderate renal impairment with eCrCl (calculated by the Cockcroft-Gault
formula using ideal body weight) 25.0 to ≤65.0 mL/min at Screening Visits 1 and 2 and
an average eCrCl for both screening visits of 30.0 to <60.0 mL/min.

6. Subject has been taking an XOI as urate-lowering therapy (ULT) indicated for the
treatment of gout for at least 4 weeks prior to Screening at a stable, medically
appropriate dose, as determined by the Investigator. The minimum dose of allopurinol
is 200 mg daily, and the minimum dose of febuxostat is the lowest approved dose per
the local product label.

7. Subject has a serum uric acid level ≥6.0 mg/dL (357 µmol/L) at Screening Visits 1 and
2.

8. Subject is male or female; females must not be pregnant or breastfeeding and females
of childbearing potential must agree to use non hormonal contraception during the
Screening Period and while taking investigation product (IP).

9. Subject has a body mass index <45 kg/m2.

Exclusion Criteria:

1. Subject had unstable angina, New York Heart Association class III or IV heart failure,
myocardial infarction, or stroke within the last 6 months prior to randomization; or
had a deep venous thrombosis within the previous 3 months prior to randomization.

2. Subject has uncontrolled hypertension (defined as systolic pressure above 160 or
diastolic pressure above 95 mm Hg at either Screening Visits 1 or 2).

3. Subject has severe hepatic impairment (defined as Child-Pugh Class C) or is known
human immunodeficiency virus (HIV) positive.

4. Subject is a solid organ transplant recipient.

5. Subject has a urine protein of 3+ or higher by dipstick by the central laboratory at
Screening Visit 2.

6. Subject has a history of glomerulonephritis.

7. Subject is taking valpromide, progabide, valproic acid, or other known inhibitors of
epoxide hydrolase, or subject is taking ranolazine, cyclosporine, azathioprine or
mercaptopurine.

8. Subject is receiving chronic treatment with more than 325 mg of salicylates per day.

9. Subject is unable to initiate gout flare prophylaxis with colchicine or low-dose oral
corticosteroids at Baseline.

10. Subject is taking any other drug approved for use as a urate-lowering medication other
than allopurinol or febuxostat (eg, pegloticase, probenecid, benzbromarone) within 4
weeks prior to Screening or during Screening.

11. For subjects who will be taking colchicine for gout flare prophylaxis: Subject is
taking, or anticipated to take during the first 6 months on study, moderate or strong
Cytochrome P450 3A4 (CYP3A4) inhibitors (ie, verapamil or diltiazem, clarithromycin,
and fluconazole; or grapefruit or grapefruit juice).

12. Subject previously participated in a clinical study involving lesinurad (RDEA594) or
verinurad (RDEA3170) and received active treatment or placebo, or has taken
commercially-available lesinurad.

13. Subject has a gout flare during the Screening Period.

14. Subject is pregnant or breastfeeding.

15. Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL]
of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).

16. Subject has a history of malignancy and has been on active treatment within the
previous 5 years prior to randomization with the exception of non-melanoma skin
cancer, treated in situ Grade 1 cervical cancer, or treated ductal carcinoma in situ
of the breast.

17. Subject has been hospitalized (other than for elective surgery) or received
intravenous contrast (eg, for CT scan or any angiography) within 1 month prior to
Screening or during Screening.

18. Subject has participated in a clinical trial within 8 weeks prior to Screening.

19. Subject has any other medical or psychological condition, which in the opinion of the
Investigator might create undue risk to the subject or interfere with the subject's
ability to comply with the protocol requirements or to complete the study.

20. The maximum number of subjects in the eCrCl stratification subgroup has been reached.